Search results for "Trial"

showing 10 items of 10525 documents

Do Mood Stabilizers Help in Borderline Personality Disorder?

2017

BackgroundDespite the relatively weak evidence base, individuals with borderline personality disorder are often treated with pharmacological interventions. Amongst the drugs, which have shown most promise, are mood stabilizers, which were one of the two drug classes with the most beneficial effects in a previous cochrane review though the robustness of findings was described as low (Stoffers et al., 2010). Here we present data on the latest evidence for mood stabilizers based on an updated cochrane review currently underway.MethodsA systematic review and meta-analysis of randomized controlled trials was conducted. All randomized comparisons of drug vs. placebo, drug vs. drug, or drug vs. a …

medicine.medical_specialtymedicine.diseasePersonality disorderslaw.inventionPsychiatry and Mental healthMoodTolerabilityRandomized controlled triallawmedicineAnxietymedicine.symptomPsychiatryAdverse effectPsychologyBorderline personality disorderPsychopathologyClinical psychologyEuropean Psychiatry
researchProduct

Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer

2007

Abstract Background. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) contribute to the invasiveness of many carcinomas. Here, we studied a possible association between cytosolic uPA and PA-1 concentrations in tumor tissue with prognosis in patients with endometrial cancer. Methods. Cytosolic concentrations of uPA and PAI-1 were determined in 69 primary endothelial adenocarcinomas using an enzyme-linked immunoassay (ELISA). A possible influence of uPA and PAI-1 was studied by multivariate Cox regression adjusting for the established clinical prognostic factors FIGO-stage, grading, depth of invasion, diabetes mellitus and age. Results. Both uPA ( …

medicine.medical_specialtymedicine.drug_classAdenocarcinomaDisease-Free SurvivalMetastasisPredictive Value of TestsGermanyInternal medicineDiabetes mellitusPlasminogen Activator Inhibitor 1Progesterone receptorBiomarkers TumormedicineHumansNeoplasm StagingUrokinasebusiness.industryProportional hazards modelEndometrial cancerObstetrics and GynecologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisUrokinase-Type Plasminogen ActivatorEndometrial NeoplasmsEndocrinologyOncologyEstrogenFemalebusinessPlasminogen activatormedicine.drugGynecologic Oncology
researchProduct

The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen

2003

OBJECTIVE To enlighten the early response of endometrium to tamoxifen by assessing the expression of estrogen receptors, progesterone receptors, Ki-67, and the histological response in endometria from normal postmenopausal women treated for 21 days with tamoxifen. DESIGN A total of 40 women, scheduled to undergo vaginal hysterectomy because of uterine prolapse, were randomly assigned to the tamoxifen group (20 mg/day; 20 women) or the control group (20 women). Samples were obtained from the upper and the lower thirds of the uterine cavity. Standard immunohistochemical staining of estrogen and progesterone receptors and of Ki-67 was performed on frozen sections. Staining was assessed using s…

medicine.medical_specialtymedicine.drug_classAdministration OralEstrogen receptorEndometriumEndometriumInternal medicineProgesterone receptormedicineHumansEstrogen receptor betabusiness.industryAntibodies MonoclonalObstetrics and GynecologyMiddle AgedImmunohistochemistryPostmenopauseTamoxifenKi-67 AntigenEndocrinologymedicine.anatomical_structureReceptors EstrogenEstrogenFemaleSimple Endometrial HyperplasiaReceptors ProgesteronebusinessEstrogen receptor alphahormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugMenopause
researchProduct

Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Info…

2019

<b><i>Background:</i></b> Breast cancer patients’ self-understanding of their disease can impact their quality of life (QoL); the relationship between compliance and QoL is poorly understood. <b><i>Patients and Methods:</i></b> The Patient’s Anastrozole Compliance to Therapy (PACT) program, a prospective, randomized study, investigated the effect of additional patient information material (IM) packages on compliance with adjuvant aromatase inhibitor (AI) therapy in postmenopausal women with hormone receptor-positive early breast cancer. The QoL subanalysis presented here examined the impact of IM packages on QoL and the association between QoL…

medicine.medical_specialtymedicine.drug_classAnastrozoleDiseasePactlaw.invention03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeRandomized controlled triallawmedicine030212 general & internal medicineAromatase inhibitorbusiness.industryCancermedicine.diseasehumanitiesOncology030220 oncology & carcinogenesisPhysical therapySurgerybusinessResearch Articlemedicine.drugBreast Care
researchProduct

Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal ho…

1999

Abstract Objective: To compare compliance, symptom control, bleeding patterns, endometrial response, and lipid changes in postmenopausal women treated with transdermal E 2 and a regimen of either intermittent or continuous dosing of progestin. Design: Randomized, prospective study. Setting: Menopausal Outpatient Clinic at an academic tertiary care hospital. Patient(s): One hundred women who had reached menopause naturally and had been amenorrheic for at least 1 year. Fifty women were randomly assigned to receive each regimen. Intervention(s): All patients received 50-μg E 2 patches and medroxyprogesterone acetate, either 5 mg twice per week or 2.5 mg daily. The bleeding pattern was register…

medicine.medical_specialtymedicine.drug_classMedroxyprogesteroneMedroxyprogesterone AcetateAdministration CutaneousEndometriumInternal medicinemedicineMedroxyprogesterone acetateOutpatient clinicHumansProspective StudiesProspective cohort studyAgedmedicine.diagnostic_testEstradiolProgesterone Congenersbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle Agedmedicine.diseaseLipidsSurgeryMenstruationMenopauseRegimenReproductive MedicinePatient ComplianceFemaleProgestinsbusinessProgestinmedicine.drugEndometrial biopsyFertility and sterility
researchProduct

Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics

2013

Background The cardiac hormone atrial natriuretic peptide (ANP) induces natriuresis, vasodilation and inhibits aldosterone through the activation of the guanylyl cyclase A receptor (GC-A) and the second messenger cGMP. ANP possesses also metabolic properties enhancing lipolysis and release of the adipokine adiponectin. Previous studies in general populations reported that the minor G allele of the ANP genetic variant rs5068 is associated with increased circulating levels of ANP and B-type natriuretic peptide, lower blood pressure (BP), and reduced risk of hypertension. We recently reported that in the general population from Olmsted County, MN, USA the G allele of rs5068 is associated not o…

medicine.medical_specialtymedicine.drug_classPopulationAdipokineBioinformaticsNatriuresischemistry.chemical_compoundAtrial natriuretic peptideInternal medicinemedicineNatriuretic peptidePharmacology (medical)educationPharmacologyeducation.field_of_studyAldosteroneAdiponectinbusiness.industrymedicine.diseaseEndocrinologychemistrycardiovascular systemOral PresentationMetabolic syndromebusinesshormones hormone substitutes and hormone antagonistsBMC Pharmacology and Toxicology
researchProduct

Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.

2007

The use of symptomatic agents has greatly improved the medical treatment of advanced cancer patients with inoperable bowel obstruction. A systematic review of studies of the most popular drugs used in the medical management of inoperable malignant bowel obstruction was performed to assess the effectiveness of these treatments and provide some lines of evidence. Randomized trials that involved patients with a clinical diagnosis of intestinal obstruction due to advanced cancer treated with these drugs were reviewed. Five reports fulfilled inclusion criteria. Three studies compared octreotide (OC) and hyoscine butylbromide (HB), and two studies compared corticosteroids (CSs) and placebo. Globa…

medicine.medical_specialtymedicine.drug_classPopulationOctreotideMuscarinic AntagonistsPlaceboSettore MED/42 - Igiene Generale E ApplicataOctreotidelaw.inventionRandomized controlled trialGastrointestinal AgentslawAdrenal Cortex HormonesInternal medicineNeoplasmsButylscopolammonium BromidemedicineHumansStage (cooking)educationinoperable malignant bowel obstruction treatmentGeneral Nursingeducation.field_of_studybusiness.industryqualitative systematic reviewCancermedicine.diseaseSurgeryBowel obstructionAnesthesiology and Pain Medicineinoperable malignant bowel obstruction treatment; qualitative systematic review; management of bowel obstructionCorticosteroidNeurology (clinical)businessIntestinal Obstructionmedicine.drugmanagement of bowel obstructionJournal of pain and symptom management
researchProduct

<p>Future perspectives of anticholinergics for the treatment of asthma in adults and children</p>

2019

Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-acting muscarinic antagonists (LAMAs) are a relatively recent addition to disease management recommendations for asthma, tiotropium has been extensively studied in a large clinic…

medicine.medical_specialtymedicine.drug_classPsychological intervention030204 cardiovascular system & hematologyAsthma managementPlacebo03 medical and health sciences0302 clinical medicineAnticholinergicMedicinePharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsDisease management (health)Intensive care medicineAsthmaChemical Health and Safetybiologybusiness.industryGeneral MedicineLamabiology.organism_classificationmedicine.diseaserespiratory tract diseasesClinical trialbusinessSafety ResearchTherapeutics and Clinical Risk Management
researchProduct

Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry

2021

Thrombosis and haemostasis 122(4), 552-559 (2022). doi:10.1055/a-1549-6556

medicine.medical_specialtymedicine.drug_classPyridonesAdministration OralHemorrhagePharmacokineticsRivaroxabanInternal medicineAtrial FibrillationmedicineHumansProspective StudiesRegistriesRivaroxabanbusiness.industryAnticoagulantAnticoagulantsHematologyEmergency situationsConfidence intervalDabigatranClinical trialApixabanObservational studybusinessmedicine.drug
researchProduct

Selective RAR agonists for acne vulgaris: A narrative review.

2019

Background Acne vulgaris is a chronic disfiguring inflammatory disease of adolescents and adults affecting up to 90% of the population around the world. The sequence of etiopathogenesis in acne is not completely understood but involves abnormalities in sebum production, follicular plugging, proliferation of propionibacterium acnes, and chronic inflammation. Aims This review aims to summarize the features of the topical selective RAR agonists in treating acne vulgaris with a special emphasis on the 4th generation topical retinoid trifarotene. Methods Studies were identified by searching electronic databases (MEDLINE and PubMed) till August 2019 and reference lists of respective articles. Onl…

medicine.medical_specialtymedicine.drug_classReceptors Retinoic AcidPopulationTretinoinDermatologyAdministration Cutaneous030207 dermatology & venereal diseases03 medical and health sciencesPropionibacterium acnesRetinoids0302 clinical medicineMaintenance therapyTazaroteneAdapaleneAcne VulgarisMedicineHumansRetinoidAdapaleneeducationAcneRandomized Controlled Trials as Topiceducation.field_of_studybiologybusiness.industryNicotinic Acidsbiology.organism_classificationmedicine.diseaseDermatologyTreatment OutcomeTolerability030220 oncology & carcinogenesisDermatologic Agentsbusinessmedicine.drugJournal of cosmetic dermatologyREFERENCES
researchProduct